FDA Approves First Drug for Treatment of Parkinson’s Dyskinesia
The US Food and Drug Administration (FDA) has approved amantadine extended-release capsules (Gocovri, Adamas Pharmaceuticals Inc) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, the company announced on 8/25/17.
“Gocovri’s approval is an important advancement for […]